Indian J Sex Transm Dis Indian J Sex Transm Dis
Official Publication of the Indian Association for the Study of Sexually Transmitted Diseases
Indian J Sex Transm Dis
The Journal | Search | Ahead Of Print | Current Issue | Archives | Instructions | Subscribe | Login    Users online: 1227   Home Email this page Print this page Bookmark this page Decrease font size Default font size Increase font size

  Table of Contents  
Year : 2022  |  Volume : 43  |  Issue : 2  |  Page : 248-249

Suspicious perianal nodule

Department of Dermatology, University Hospital of Leon, León, Spain

Date of Submission29-Dec-2021
Date of Decision28-Jan-2022
Date of Acceptance07-Feb-2022
Date of Web Publication17-Nov-2022

Correspondence Address:
Dr. Ruben Linares Navarro
University Hospital of Leon, Dermatology Department, Calle Altos De Nava, S/N, 24008, León
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijstd.ijstd_115_21

Rights and Permissions


How to cite this article:
Navarro RL, Ramírez GR, Valladares Narganes LM, Rodríguez Prieto M&. Suspicious perianal nodule. Indian J Sex Transm Dis 2022;43:248-9

How to cite this URL:
Navarro RL, Ramírez GR, Valladares Narganes LM, Rodríguez Prieto M&. Suspicious perianal nodule. Indian J Sex Transm Dis [serial online] 2022 [cited 2023 Sep 21];43:248-9. Available from:

   Case Description Top

A 32-year-old man with a history of hidradenitis suppurativa Hurley III, receiving antibiotic and surgical treatments. The patient sought medical advice for a new nodule in perianal region which had grown during the past 2 months. He gave a history of regular unprotected receptive anal intercourse.

Physical examination revealed an ulcerated, firm, violaceous nodule adjacent to anus [Figure 1]. He also presented with sinus tracks in the inguinal region and perineum due to hidradenitis and a diffuse maculopapular eruption. No adenopathies were detected.
Figure 1: Ulcerated, firm, violaceous nodule adjacent to anus

Click here to view

Different microbiologic tests and biopsy of the nodule were performed. Results for HIV and syphilis (treponemal and nontreponemal) were positive. CSF examination was normal. Our patient received penicillin and antiretroviral therapy.

Biopsy revealed a diffuse infiltrate of medium-large size atypical cells in the dermis and subcutis, with sparing epidermis. Cells showed eccentric nucleus with clumped chromatin, prominent nucleolus, abundant and basophilic cytoplasm, and frequent mitoses [Figure 2]. Immunohistochemistry was positive for CD45, CD38, CD138, and Epstein–Barr Virus (EBV). Cells were negative for CD20, CD3, CD5, CD30, bcl-6, and Pax5.
Figure 2: Diffuse infiltrate of medium-large size atypical lymphoid cells in dermis and subcutis, sparing epidermis (hematoxylin-eosin, original magnification, ×200)

Click here to view

What is your Diagnosis?

   Diagnosis Top

Perianal plasmablastic lymphoma in hidradenitis suppurativa area.

   Discussion Top

Plasmablastic lymphoma is a rare entity associated with immunosuppression, especially with HIV. It is also related with EBV and Human Herpesvirus 8 infection. Tumor cells are positive for CD45, CD38, and CD138, while CD20, CD3, CD5, CD30, bcl-6, and Pax5 are usually negative.[1]

Oral cavity is the most frequent location, followed by lymph nodes, gastrointestinal tract. Tumors affecting only the skin are less common.[2] They usually present over the legs as erythematous-violaceous nodules with a tendency to ulcerate.

Positron emission tomography-computed tomography and bone marrow biopsy showed no signs of progression. He was treated with bortezomib, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and radiotherapy, with satisfactory response.

Some studies have proven association between hidradenitis suppurativa and lymphoma.[3],[4] Chronic inflammation in perianal area due to hidradenitis might explain this location.

Prognosis of this lymphoma is poor. Accepted therapies include CHOP, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, lenalidomide and bortezomib.[5]

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

   References Top

Sukswai N, Lyapichev K, Khoury JD, Medeiros LJ. Diffuse large B-cell lymphoma variants: An update. Pathology 2020;52:53-67.  Back to cited text no. 1
Harmon CM, Smith LB. Plasmablastic lymphoma: A review of clinicopathologic features and differential diagnosis. Arch Pathol Lab Med 2016;140:1074-8.  Back to cited text no. 2
Jung JM, Lee KH, Kim YJ, Chang SE, Lee MW, Choi JH, et al. Assessment of overall and specific cancer risks in patients with hidradenitis suppurativa. JAMA Dermatol 2020;156:844-53.  Back to cited text no. 3
Tannenbaum R, Strunk A, Garg A. Association between hidradenitis suppurativa and lymphoma. JAMA Dermatol 2019;155:624-5.  Back to cited text no. 4
Makady NF, Ramzy D, Ghaly R, Abdel-Malek RR, Shohdy KS. The emerging treatment options of plasmablastic lymphoma: Analysis of 173 individual patient outcomes. Clin Lymphoma Myeloma Leuk Mar; 21(3):e255-e263.  Back to cited text no. 5


  [Figure 1], [Figure 2]


Print this article  Email this article


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (1,268 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

   Case Description
    Article Figures

 Article Access Statistics
    PDF Downloaded11    
    Comments [Add]    

Recommend this journal